These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

358 related articles for article (PubMed ID: 33906726)

  • 21. Brentuximab vedotin.
    Ansell SM
    Blood; 2014 Nov; 124(22):3197-200. PubMed ID: 25293772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study.
    Fanale MA; Horwitz SM; Forero-Torres A; Bartlett NL; Advani RH; Pro B; Chen RW; Davies A; Illidge T; Huebner D; Kennedy DA; Shustov AR
    J Clin Oncol; 2014 Oct; 32(28):3137-43. PubMed ID: 25135998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.
    Jacobsen ED; Sharman JP; Oki Y; Advani RH; Winter JN; Bello CM; Spitzer G; Palanca-Wessels MC; Kennedy DA; Levine P; Yang J; Bartlett NL
    Blood; 2015 Feb; 125(9):1394-402. PubMed ID: 25573987
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New uses for brentuximab vedotin and novel antibody drug conjugates in lymphoma.
    Merli M; Ferrario A; Maffioli M; Olivares C; Stasia A; Arcaini L; Passamonti F
    Expert Rev Hematol; 2016 Aug; 9(8):767-80. PubMed ID: 27416486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
    Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
    J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Brentuximab vedotin in the treatment of CD30+ PTCL.
    Barta SK; Gong JZ; Porcu P
    Blood; 2019 Dec; 134(26):2339-2345. PubMed ID: 31697814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies.
    Gualberto A
    Expert Opin Investig Drugs; 2012 Feb; 21(2):205-16. PubMed ID: 22127011
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.
    Bartlett NL; Chen R; Fanale MA; Brice P; Gopal A; Smith SE; Advani R; Matous JV; Ramchandren R; Rosenblatt JD; Huebner D; Levine P; Grove L; Forero-Torres A
    J Hematol Oncol; 2014 Mar; 7():24. PubMed ID: 24642247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma.
    Jagadeesh D; Horwitz S; Bartlett NL; Kim Y; Jacobsen E; Duvic M; Little M; Trepicchio W; Fenton K; Onsum M; Lisano J; Advani R
    Oncologist; 2022 Oct; 27(10):864-873. PubMed ID: 35948003
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The epidemiology and targeted therapies for relapsed and refractory CD30+ lymphomas.
    Macalalad AR; McAuliffe M; Yang H; Kageleiry A; Zhong Y; Wu EQ; Shonukan O; Bonthapally V
    Curr Med Res Opin; 2015 Mar; 31(3):537-45. PubMed ID: 25598441
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase I/II clinical trial of brentuximab vedotin for pretreated Japanese patients with CD30-positive cutaneous T-cell lymphoma.
    Hirai Y; Sakurai J; Yoshida S; Kikuchi T; Mitsuhashi T; Miyake T; Fujimura T; Abe R; Fujikawa H; Boki H; Suga H; Shibata S; Miyagaki T; Shimauchi T; Kiyohara E; Kawakami Y; Morizane S
    J Dermatol; 2024 Aug; 51(8):1037-1049. PubMed ID: 38874430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Brentuximab vedotin for treatment of systemic T-cell lymphoma.
    Chihara D; Oki Y
    Expert Opin Biol Ther; 2014 Oct; 14(10):1519-26. PubMed ID: 25200691
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Brentuximab vedotin: delivering an antimitotic drug to activated lymphoma cells.
    Ansell SM
    Expert Opin Investig Drugs; 2011 Jan; 20(1):99-105. PubMed ID: 21121873
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas.
    Younes A; Bartlett NL; Leonard JP; Kennedy DA; Lynch CM; Sievers EL; Forero-Torres A
    N Engl J Med; 2010 Nov; 363(19):1812-21. PubMed ID: 21047225
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarker-driven management strategies for peripheral T cell lymphoma.
    Mulvey E; Ruan J
    J Hematol Oncol; 2020 May; 13(1):59. PubMed ID: 32448357
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.
    Horwitz S; O'Connor OA; Pro B; Illidge T; Fanale M; Advani R; Bartlett NL; Christensen JH; Morschhauser F; Domingo-Domenech E; Rossi G; Kim WS; Feldman T; Lennard A; Belada D; Illés Á; Tobinai K; Tsukasaki K; Yeh SP; Shustov A; Hüttmann A; Savage KJ; Yuen S; Iyer S; Zinzani PL; Hua Z; Little M; Rao S; Woolery J; Manley T; Trümper L;
    Lancet; 2019 Jan; 393(10168):229-240. PubMed ID: 30522922
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed CAR-T cell therapy in relapsed/refractory ALK+ ALCL.
    Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
    Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of relapsed or refractory hodgkin lymphoma with second-generation antibody-drug conjugates: focus on brentuximab vedotin.
    Mei M; Thomas S; Chen R
    BioDrugs; 2014 Jun; 28(3):245-51. PubMed ID: 24258497
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.